Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05734781
Other study ID # HSEARS20221217002
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 4, 2023
Est. completion date December 2024

Study information

Verified date February 2024
Source The Hong Kong Polytechnic University
Contact Joyce Chung, PhD
Phone 852-2766-6322
Email okjoyce.chung@polyu.edu.hk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to explore experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers. The main question it aims to answer is: • What are the experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers? Participants will be invited to either semi-structured in-depth interviews or focus group discussions to share their thoughts.


Description:

Objectives: To explore stakeholders' (patients, families and healthcare providers) experiences and perceptions of end-of-life communication in China; and understand culturally appropriate communication strategies. Design and subjects: This study is a qualitative study. Eligible patients, family caregivers and healthcare providers will be recruited in two hospitals. Purposive sampling methods will be adopted. Semi-structured in-depth interviews with patients and family caregivers will be conducted respectively. Focus group discussions will be arranged with healthcare providers, allowing them to discuss end-of-life communication and generate group interactions and creative thinking. Data analysis: The data analysis will be an iterative, cyclic and self-reflective process. Using inductive thematic analysis, common themes and categories will be determined through inductive reasoning and constant comparison. Expected results: The study will fill the gap of no empirical evidence on end-of-life communication strategies from a Chinese perspective and enrich the knowledge about end-of-life communication.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients: - Be aged older than 18 years - Have a defined incurable life-limiting illness with a likely life expectancy of fewer than 12 months (National Institute for Health and Care Excellence, 2021), according to the consultation with the patient's physician - Have been informed of disease diagnosis and treatment - Be able to speak Mandarin and express clearly - Be able to provide informed consent Family caregivers: - Be aged older than 18 years - One of the terminally ill patient's primary family caregivers who are familiar with patient's situation, which is defined as lived with or visited patients at least twice a week in the past month - Have been informed of patient's disease diagnosis and treatment - Be able to speak Mandarin - Be able to provide informed consent Healthcare providers: - Be nurses, physicians or other healthcare professionals - Be experienced in providing treatment or care to patients with advanced, life-limiting illnesses (whose likely life expectancies of fewer than 12 months) and family caregivers of such patients for at least five years (Koh et al., 2016) - Consent to participate in the study Exclusion Criteria: Patients and family caregivers: - Severe auditory impairment - Cognitive impairment

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Not Application as this is a qualitative study
Not Application as this is a qualitative study

Locations

Country Name City State
China Zhejiang Cancer Hospital Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
The Hong Kong Polytechnic University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Qualitative data and participants basic information Interviews and focus group discussions will be conducted to collect qualitative data Through study completion, an average of 12 months
See also
  Status Clinical Trial Phase
Terminated NCT00982995 - Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients Phase 2
Completed NCT00121004 - A Study to Tailor Advance Directives N/A
Completed NCT02036281 - A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain Phase 1